Joe McCann
Long/short equity, growth, medium-term horizon

Cologuard Will Dominate Its Addressable Market

The last few weeks have seen a heated debate on Seeking Alpha and Twitter regarding the prospects of Exact Sciences' (NASDAQ:EXAS) Cologuard, once the seemingly inevitable FDA approval comes June 6th. Looking at the Bull vs. Bear argument in the market, I found myself initially inclined to be skeptical of the prospects for a test that was cutting the market by a 3rd (once every 3 years vs. annual) and 20 times the cost of the current standard of care. My experiences with the BRCA test and Sequenom's (NASDAQ:SQNM) Maternit21 launch left me generally bearish on a diagnostic launch.

However, a long time ago, I learned that one can't rely on which argument made by other...

Join Seeking Alpha PRO to read this archived article and 11,574 other archived articles
FREESA PRO MEMBERS
IDEA GENERATORXExclusive access to 10 PRO ideas every day
INVESTING IDEAS LIBRARYXExclusive access to PRO library of more than 15,000 ideas
SECTOR EXPERT NETWORKXExclusive access to all sector experts for direct consultation
PERFORMANCE TRACKINGXTrack performance of all PRO stock ideas
PROFESSIONAL TOOLSXProfessional Idea Filters to zero-in based on industry, market cap and more
"In just the first month of using PRO, I used it to generate two ideas which were actionable for me. As a result of these two positions, I have earned more than 20 times the annual subscription costs for PRO."Michael Yagemann, Greenbridge Capital
"I am pleasantly surprised with the scope of small and mid-cap coverage PRO offers. You can't find that any where else."Patrick Rice, Mainstay Capital Management
You may cancel at any time for any reason, and receive a prompt refund for membership on months paid and not used (max. 6 months). Details